发明名称 USE OF HEPARIN OR NONANTICOAGULANT HEPARIN FOR INHIBITING APOPTOSIS ARISING FROM ISCHEMIA PERFUSION INJURY
摘要 Heparin reduces ischemia-reperfusion injury to myocardium. This effect has been attributed complement inhibition, but heparin also has other activities that might diminish ischemia-reperfusion. To further probe these mechanisms, we compared heparin and an O-desulfated nonanticoagulant heparin with greatly reduced anti-complement activity. Given at the time of coronary artery reperfusion in a canine model of myocardial infarction, both heparin and O-desulfated heparin equally reduced neutrophil adherence to ischemic-reperfused coronary artery endothelium, influx of neutrophils into ischemic-reperfused myocardium, myocardial necrosis and release of creatine kinase into plasma. Heparin and O-desulfated heparin also prevented dysfunction of endothelial-dependent coronary relaxation following ischemic injury. In addition, heparin and O-desulfated heparin inhibited translocation of the transcription factor NF-.KAPPA.B from cytoplasm to the nucleus in human endothelial cells and decreased NF-.KAPPA.B DNA binding in human endothelium and ischemic-reperfused rat myocardium. Thus, heparin and nonanticoagulant heparin decrease ischemia-reperfusion injury by disrupting multiple levels of the inflammatory cascade, including the novel observation that heparins inhibit activation of the pro-inflammatory transcription factor NF-.KAPPA.B.
申请公布号 CA2407806(C) 申请公布日期 2012.04.17
申请号 CA20012407806 申请日期 2001.04.30
申请人 CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D.B.A. CAROLINAS MEDICAL CENTER 发明人 KENNEDY, THOMAS P.
分类号 A61K31/727;A61P9/04;A61P9/10;A61P43/00;C08B37/10 主分类号 A61K31/727
代理机构 代理人
主权项
地址